Takeda Pharmaceutical will integrate two wholly-owned subsidiaries, Takeda San Diego (TSD) and Takeda San Francisco (TSF) on January 1, 2012. TSD will become the surviving company and change its name to Takeda California (TCAL) the same day. Keith Wilson, current president of TSD, will become the president of the new company.

TSD was established in March 2005 by acquiring U.S. Syrrx, which was applying the high-speed X-ray protein crystal structure analysis technology towards the design of potential new medicines. TSD has since contributed to the in-house development of R&D pipelines such as SYR-322, treatment for type 2 diabetes. TSF was established in November 2007 to build a sophisticated technology platform for discovery, activity enhancement, and manufacturing of antibody therapeutics.

"Establishment of TCAL has enhanced the research system in the U.S." said Paul Chapman, general manager of the pharmaceutical research division. "We will accelerate our efforts to create innovative drugs to fulfill unmet medical needs while maximizing the synergy of the research activities following the integration, and enhancing the research networks among Japan, U.S., Europe, and Asia based on the Shonan Research Center."